Semax Mitigates Behavioral and Brain Changes from Early Antidepressant Exposure

Early-life exposure to antidepressants like fluvoxamine can induce significant neurodevelopmental alterations and behavioral deficits, mimicking aspects of early-life stress. These changes are often linked to neurochemical imbalances and may contribute to neuropsychiatric disorders later in life. This study investigates whether Semax can mitigate the long-term behavioral and neurochemical consequences of early-life fluvoxamine exposure.

Early-life fluvoxamine exposure significantly induced anxiety-like behaviors, impaired spatial memory, and altered locomotor activity in the white rats compared to control animals. Neurochemically, these fluvoxamine-exposed rats showed increased dopamine (DA) and serotonin (5-HT) turnover in the prefrontal cortex and hippocampus, alongside disrupted GABA levels. Semax treatment remarkably attenuated these adverse effects, leading to a significant reduction in anxiety-like behavior and a marked improvement in spatial memory compared to the untreated fluvoxamine group. Furthermore, Semax normalized the neurochemical imbalances, restoring dopamine and serotonin turnover and GABA levels in key brain regions to near control levels. This suggests Semax effectively counteracted the long-term neurodevelopmental impact of early antidepressant exposure.